ChromaDex Corporation ( (NAGE) ) has released its Q2 earnings. Here is a breakdown of the information ChromaDex Corporation presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Niagen Bioscience, Inc. is a global bioscience company focused on healthy aging, specializing in the research and development of nicotinamide adenine dinucleotide (NAD+) precursors, including its flagship ingredient Niagen®. The company operates in the health and wellness sector, offering products that aim to enhance cellular metabolism and promote longevity.
In its second-quarter 2025 financial results, Niagen Bioscience reported a significant increase in net sales and profitability, with net sales rising by 37% to $31.1 million and net income reaching $3.6 million, compared to a breakeven position in the previous year. The company also raised its full-year revenue growth outlook, reflecting strong market demand and strategic initiatives.
Key financial highlights include a 480 basis point increase in gross margin to 65.0%, a substantial 221% rise in adjusted EBITDA to $5.0 million, and a notable improvement in sales efficiency as marketing expenses decreased as a percentage of net sales. The company also reported a strong cash position, ending the quarter with $60.5 million in cash, driven by robust operational cash flows.
Strategically, Niagen Bioscience made significant advancements, including a worldwide exclusive license agreement for developing Niagen® as a potential therapy for Parkinson’s disease and the completion of patient dosing in a major Phase III clinical trial. The company also expanded its presence in the luxury hospitality sector and increased the availability of its Niagen Plus products in wellness clinics.
Looking ahead, Niagen Bioscience remains optimistic about its growth prospects, with expectations of continued expansion in e-commerce and partnerships. The company plans to maintain strategic investments in brand awareness and research and development to drive future innovation and market leadership in the NAD+ sector.